Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab consolidation after concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer
ChiCTR2300075011Phase 4Recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of adebrelimab in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shandong Cancer Hospital. Primary endpoint: progression-free survival. Started Aug 2023; status: recruiting.
02
Drugs
adebrelimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2300075011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075011.